Alcobra Ltd. (ADHD) Set to Announce Quarterly Earnings on Wednesday
Alcobra Ltd. (NASDAQ:ADHD) is scheduled to be issuing its quarterly earnings data on Wednesday, August 16th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter.
Alcobra (NASDAQ:ADHD) last issued its quarterly earnings data on Tuesday, May 30th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. On average, analysts expect Alcobra to post $-0.57 EPS for the current fiscal year and $-0.54 EPS for the next fiscal year.
Alcobra Ltd. (NASDAQ:ADHD) opened at 1.02 on Wednesday. The company’s market capitalization is $28.11 million. The firm has a 50-day moving average of $1.12 and a 200 day moving average of $1.15. Alcobra Ltd. has a one year low of $0.83 and a one year high of $5.36.
A number of analysts have recently issued reports on the stock. Jefferies Group LLC reissued a “hold” rating and set a $1.25 target price on shares of Alcobra in a research note on Monday, June 12th. ValuEngine lowered shares of Alcobra from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Zacks Investment Research raised shares of Alcobra from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research note on Friday, June 2nd. Roth Capital set a $4.00 target price on shares of Alcobra and gave the company a “buy” rating in a research note on Wednesday, May 31st. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $1.00 target price on shares of Alcobra in a research note on Thursday, April 13th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $1.93.
WARNING: “Alcobra Ltd. (ADHD) Set to Announce Quarterly Earnings on Wednesday” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/09/alcobra-ltd-adhd-set-to-announce-quarterly-earnings-on-wednesday.html.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.